In this issue:
Retention of DMARDs with RA-associated interstitial lung disease
TNF inhibitor beneficial effects on cardiovascular lipoprotein profile
Malignancy risk with tofacitinib vs TNF inhibitors
Retreatment and recapture with ixekizumab after withdrawal
Golimumab with and without concomitant methotrexate
TNF inhibitor-associated disease modification in axial SpA
Two-year tapered course of tocilizumab for giant cell arteritis
Low-dose rituximab for refractory idiopathic inflammatory myopathies
Etanercept for suspected non-radiographic axial SpA
COVID-19 vaccine responses in biological and tsDMARD recipients
Australian attitudes to biologic therapy and biosimilars
Please login below to download this issue (PDF)